Incyte

“This was a business that was owned by Incyte”

Roper's newly acquired CentralReach was previously owned by biotech Incyte, which sold the ABA-therapy software business to Roper for $1.65 billion net of a tax benefit.

“we signed a collaboration with Enable late last year, I believe in October, to use their infused device, which will allow very high volumes of infusion by the patients at home without the need to go to the doctor's office.”

Incyte partnered with Enable (Injections) to use its infusion device for a self-administered subcutaneous formulation of its 989 CALR program, a delivery-device collaboration.

“First, we're really pleased to strike a partnership with Enable. They specialize in high-volume subcutaneous administration with products with a range of 5 ml to 25 ml.”

Incyte partnered with Enable Injections for its enFuse on-body subcutaneous delivery device to support 989 and other pipeline programs.

“If you look at the Rezurock curve, when it launched, we're virtually right on top of it. That product -- they had a tough quarter, but it's roughly a $500 million business.”

Incyte benchmarked its Niktimvo GvHD launch against Sanofi's competing Rezurock, noting Rezurock is a ~$500M franchise that had a soft quarter.

“particularly when you look in the context of superior efficacy that we've seen for some of the currently approved therapies such as BIMZELX?”

An analyst probes how povorcitinib's hidradenitis suppurativa data compares against UCB's Bimzelx, a currently-approved competing therapy with reported superior efficacy data.

“We're not, for example, with povorcitinib, copying all the indications for RINVOQ.”

Management contrasts its selective indication strategy for povorcitinib with AbbVie's broader RINVOQ label, positioning against a key JAK-inhibitor competitor.

“The product's got 20,000 users in the United States, prescribers, which is second to only DUPIXENT in AD.”

Management positions Opzelura's prescriber base as second only to Dupixent in atopic dermatitis, underscoring Dupixent's continued market leadership in the category.

“my expectations are, when you look at a product like Rezurock at Sanofi, that could be the low watermark for us. And I think if you get these additional indications, then you're going to travel north of that.”

Management frames Sanofi's Rezurock peak sales as a conservative floor for Niktimvo's own long-term revenue potential, implying Niktimvo could exceed Rezurock's ceiling.

“If you take a look at the adoption curve, for example, of Sanofi' Rezurock and you look at the adoption curve right now for Niktimvo, they're both in the same ZIP code.”

Management benchmarks Niktimvo's launch trajectory directly against Sanofi's Rezurock, implying the two GVHD drugs are tracking similarly in early adoption.

“Additionally, we have established a collaboration with QIAGEN to develop a co-diagnostic across MPN, with an initial focus in CALR mutations.”

New diagnostics partnership gives QIAGEN a companion-diagnostic role tied to Incyte's CALR-mutant MPN pipeline (989), a modest incremental revenue and strategic-relevance signal for QIAGEN.

“During the second quarter, we recorded a benefit of $242 million from the contract dispute settlement with Novartis, relating to Jakafi royalty payments through the first quarter of 2025. The settlement also resulted in a reduction in COGS, driven by an ongoing 50% reduction in the royalty rate payable to Novartis.”

Incyte resolved a royalty dispute with Novartis over Jakafi, recording a one-time financial benefit and securing an ongoing 50% cut to the royalty rate it pays Novartis, a durable margin tailwind for Incyte at Novartis's expense.

“The challenge with the data that has been reported in the past with Humira and when you discuss this between physicians is that, while the response rate that has been reported was high and which has not been replicated since the original study, the drug failure on Humira is relatively fast.”

Incyte's CEO framed AbbVie's Humira as having disappointing real-world durability in hidradenitis suppurativa, positioning Incyte's povorcitinib as a differentiated alternative in that market.

“Last month, we and our partners Syndax announced that the FDA approved Niktimvo in 9 milligram and 22 milligram vials sizes, paving the way for the commercial launch.”

Incyte co-developed and is co-commercializing Niktimvo with partner Syndax; the FDA approval and launch is a near-term revenue driver shared under a profit-share agreement.